The week in pharma: action, reaction and insight – week to February 7

9 February 2025

By Barbara Obstoj-Cardwell. Editor

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical company focused on immune-mediated diseases. Last week also saw the release of fourth-quarter and full-year 2024 financial results by many pharma companies, including the US giants Merck & Co and Pfizer, as well as the two biggest players in the fast-growing weight management sector, Novo Nordisk and Eli Lilly.

Creative Acelyrin deal strengthens war chest ahead of key 2026 data catalysts

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK